Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Quantum Leap Energy Expands into Nuclear Fuel with New Advisory Board Member

Asp Isotopes said its wholly owned subsidiary Quantum Leap Energy appointed Dr. Peter S. Fiske to its strategic advisory board as the company expands its push into nuclear fuel technologies and government partnerships.

Fiske’s background includes leading the U.S. Department of Energy’s 5-year, $110 million National Alliance for Water Innovation at Lawrence Berkeley National Laboratory. He also served as chief executive officer of Pax Water Technologies and co-founded Rapt Industries, where the company licensed technology to major semiconductor equipment manufacturers and recorded its first product sales.

The appointment follows several recent moves at Quantum Leap Energy, including the formation of its strategic advisory board, the hiring of Dr. Nate Salpeter as chief technology officer, and a collaboration with the University of Bristol on a lithium laser research facility in the U.K.

Quantum Leap Energy said it is targeting front-end nuclear fuel activities including uranium conversion, enrichment of uranium-235 for HALEU, LEU+ and LEU, and isotopic separation of lithium-6 and lithium-7, along with back-end radioactive waste treatment technologies. The company said it holds exclusive global rights to its aerodynamic separation process and laser-based quantum enrichment technologies.

The company also pointed to existing strategic partnerships and commercial relationships with TerraPower, Fermi America and South Africa’s NECSA as it works to commercialize critical isotopes for advanced nuclear reactors, small modular reactors and fusion systems. Following these announcements, the company's shares moved 5.36%, and are now trading at a price of $5.405. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS